View Exam | PowerPak

1. Which of the following is recommended for a 70-year-old patient with ASCVD according to the ACC/AHA guidelines?

A. Treating to an LDL-C <70 mg/dL B. Treating to a non-HDL-C of <100 mg/dL C. Moderate-intensity statin therapy D. High-intensity statin therapy

2. Which of the following statin regimens is considered a moderate-intensity statin regimen?

A. Atorvastatin 80 mg daily B. Pravastatin 40 mg daily C. Rosuvastatin 20 mg daily D. Simvastatin 10 mg daily

3. According to the NLA recommendations, a patient with one major ASCVD risk factor and type 2 diabetes has which treatment goal?

A. LDL-C <100 mg/dL B. Non-HDL-C <100 mg/dL C. Apo B <80 mg/dL D. No lipid goal; just use moderate-to-high intensity statin therapy

4. Which of the following is an NLA-identified risk indicator?

A. Women age ≥55 years B. Lipoprotein(a) <50 mg/dL C. HDL-C <40 mg/dL in men D. High-sensitivity C-reactive protein ≥2.0 mg/L

5. A 65 year old woman with a history of an ischemic stroke and type 2 diabetes presents for follow-up. She has never been on lipid-lowering drug therapy and her current LDL-C is 90 mg/dL. Which of the following regimens is recommended by both the ACC/AHA guidelines and the NLA recommendations for lipid-lowering therapy in this woman?

A. Rosuvastatin 5 mg daily B. Atorvastatin 40 mg daily C. Simvastatin 40 mg daily with ezetimibe 10 mg daily D. No lipid-lowering therapy because her LDL-C concentration is low enough

6. Which of the following lipid-lowering drugs will reduce LDL-C concentrations the most?

A. Alirocumab B. Colesevelam C. Ezetimibe D. Niacin

7. A patient is started on statin therapy. After 4 weeks the patient complains of muscle pain and soreness. A serum CK value is 250 IU/L (normal range is 0–200 IU/L), and this patient's pre-statin serum CK value was 150 IU/L. According to the NLA Statin Safety Task Force, this patient has which of the following?

A. Myopathy B. Mild myonecrosis C. Myalgia D. Clinical rhabdomyolysis

8. Which of the following is most accurate about statin-associated new-onset diabetes?

A. A history of diabetes is a contraindication to using statin therapy. B. Risk of new-onset diabetes is the same with atorvastatin 10 mg and 80 mg. C. Patients who are obese are at the same risk as those who are normal weight. D. The overall benefits of CV event lowering outweigh the new-onset diabetes risk.

9. An 8-year-old boy is diagnosed with familial hypercholesterolemia, and has an LDL-C value of 195 mg/dL. He is started on aggressive lifestyle modifications. Which of the following lipid-lowering regimens is most appropriate for him?

A. Atorvastatin 80 mg daily B. Pravastatin 20 mg daily C. Rosuvastatin 5 mg daily D. Wait until he is age 10 to start drug therapy

10. Which of the following is true about statin therapy in older patients?

A. No statin has lower recommended doses based on age within the product labeling. B. With most statins, serum drug concentrations decrease as age increases. C. ACC/AHA guidelines recommends against statin therapy in all primary prevention patients at age 75 and older. D. NLA recommends all patients age 75 and older receive at low-intensity statin therapy for primary prevention.